DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

Open Access
Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs
Majed M. Khraishi, Valencia P. Remple, Samuel Silverberg, Jacqueline C. Stewart, Brandusa Florica and Louis Bessette

The Journal of Rheumatology May 1 2022, 49 (5) 454-464; DOI: https://doi.org/10.3899/jrheum.200609
Open Access
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND
Désirée van der Heijde, Cynthia E. Kartman, Li Xie, Scott Beattie, Douglas Schlichting, Daojun Mo, Patrick Durez, Yoshiya Tanaka and Roy Fleischmann

The Journal of Rheumatology February 1 2022, 49 (2) 133-141; DOI: https://doi.org/10.3899/jrheum.210346
You have access
Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset
Hedley Griffiths, Tegan Smith, Christopher Mack, Jo Leadbetter, Belinda Butcher, Mustafa Acar and Sabina Ciciriello

The Journal of Rheumatology February 1 2022, 49 (2) 150-156; DOI: https://doi.org/10.3899/jrheum.201551
You have access
Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience
Stylianos T. Panopoulos, Maria G. Tektonidou, Vasiliki-Kalliopi Bournia, Aikaterini Arida and Petros P. Sfikakis

The Journal of Rheumatology January 1 2022, 49 (1) 68-73; DOI: https://doi.org/10.3899/jrheum.210273
You have access
Effectiveness of a Second Biologic After Failure of a Non–tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis
Katerina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, Daniela Di Giuseppe, Karin Hellgren, Bente Glintborg, Dan Nordström, Ritva Peltomaa, Kalle Aaltonen, Nina Trokovic, Eirik K. Kristianslund, Tore K. Kvien, Sella A. Provan, Bjorn Gudbjornsson, Gerdur Grondal, Lene Dreyer, Lars Erik Kristensen, Tanja Schjødt Jørgensen, Lennart T.H. Jacobsson and Johan Askling

The Journal of Rheumatology October 1 2021, 48 (10) 1512-1518; DOI: https://doi.org/10.3899/jrheum.201467
You have access
Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis
Nicolino Ruperto, Hermine I. Brunner, Nikolay Tzaribachev, Gabriel Vega-Cornejo, Ingrid Louw, Rolando Cimaz, Jason Dare, Graciela Espada, Enrique Faugier, Manuel Ferrandiz, Valeria Gerloni, Pierre Quartier, Clovis Artur Silva, Linda Wagner-Weiner, Yash Gandhi, Julie Passarell, Marleen Nys, Robert Wong, Alberto Martini and Daniel J. Lovell for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO)

The Journal of Rheumatology July 1 2021, 48 (7) 1073-1081; DOI: https://doi.org/10.3899/jrheum.200154
You have access
Relationship Between Depression and Disease Activity in United States Veterans With Early Rheumatoid Arthritis Receiving Methotrexate
Alan M. Rathbun, Bryant R. England, Ted R. Mikuls, Alice S. Ryan, Jennifer L. Barton, Michelle D. Shardell and Marc C. Hochberg

The Journal of Rheumatology June 1 2021, 48 (6) 813-820; DOI: https://doi.org/10.3899/jrheum.200743
You have access
Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis
Maxime M.A. Verhoeven, Janneke Tekstra, Jacob M. van Laar, Attila Pethö-Schramm, Michelle E.A. Borm, Johannes W.J. Bijlsma, Johannes W.G. Jacobs, Floris P.J.G. Lafeber and Paco M.J. Welsing

The Journal of Rheumatology April 1 2021, 48 (4) 495-503; DOI: https://doi.org/10.3899/jrheum.200067
You have access
Improving Hydroxychloroquine Dosing and Toxicity Screening at a Tertiary Care Ambulatory Center: A Quality Improvement Initiative
Sahil Koppikar, Stephanie Gottheil, Chandra Farrer and Natasha Gakhal

The Journal of Rheumatology January 1 2021, 48 (1) 138-144; DOI: https://doi.org/10.3899/jrheum.191265
You have access
Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset
Peter Youssef, Bruno Marcal, Peter Button, Matt Truman, Paul Bird, Hedley Griffiths, Lynden Roberts, Kathleen Tymms and Geoff Littlejohn

The Journal of Rheumatology August 1 2020, 47 (8) 1174-1181; DOI: https://doi.org/10.3899/jrheum.190535

Main menu

User menu

Search

DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

Pages

Content

Resources

Subscribers

More